Terms: = Sarcomas AND RALGDS, FLJ20922, 5900, ENSG00000160271, RalGEF, RGF, Q12967 AND Clinical Outcome
1 results:
1. Oncogenic and RASopathy-associated K-RAS mutations relieve membrane-dependent occlusion of the effector-binding site.
Mazhab-Jafari MT; Marshall CB; Smith MJ; Gasmi-Seabrook GM; Stathopulos PB; Inagaki F; Kay LE; Neel BG; Ikura M
Proc Natl Acad Sci U S A; 2015 May; 112(21):6625-30. PubMed ID: 25941399
[TBL] [Abstract] [Full Text] [Related]
